Hidetomo Murakami

Hidetomo Murakami

Auto-generated profile, based on publicly available information

Hidetomo Murakami

Showa University, Tokyo Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
KNKoji Nakashima
Koji Nakashima
TNTakato Nakajo
Takato Nakajo
MKMichiari Kawamo
Michiari Kawamo
AKAkihito Kato
Akihito Kato
SISeiichiro Ishigaki
Seiichiro Ishigaki
HIHitoshi Izumiyama
Hitoshi Izumiyama
Cerebrospinal fluid (CSF) shunts are frequently used to treat hydrocephalus. The use of a programmable shunt valve allows physicians to easily change the opening pressure. Since patients with adjustable CSF shunt valves may use portable game machines, the permanent magnets in these machines may alter the shunt valve programmed settings or permanently damage the device. This study investigated the risk of unintentional valve adjustment associated with the use of game machines in patients with programmable CSF shunt valves. Four adjustable valves from 4 different manufacturers, Sophysa Polaris model SPV (Polaris valve), Miethke proGAV (proGAV), Codman Hakim programmable valve (CHPV), and Strata II small valve (Strata valve), were evaluated. Magnetic field interactions were determined using the portable game machine, Nintendo DS Lite (DS). The maximum distance between the valve and the DS that affected the valve pressure setting was measured by x-ray cinematography. The Polaris valve and proGAV were immune to unintentional reprogramming by the DS. However, the settings of the CHPV and Strata valves were randomly altered by the DS. Patients with an implanted shunt valve should be made aware of the risks posed by the magnetic fields associated with portable game machines and commonly used home electronics.

1 October 2017 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
HMHidetomo Murakami
Hidetomo Murakami
TNTetsuhito Nohara
Tetsuhito Nohara
HSHidenobu Shozawa
Hidenobu Shozawa
YOYoshiyuki Owan
Yoshiyuki Owan
TKTakeshi Kuroda
Takeshi Kuroda
Kenjiro OnoKenjiro Ono
Kenjiro Ono
Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in patients with Parkinson’s disease (PD) are inconsistent. Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). Methods: PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems. All participants were tested prior to and at 4–7 months after the drug initiation/adjustment. Executive function was assessed by using the Behavioral Assessment of the Dysexecutive Syndrome (BADS). Motor function was assessed by using the Unified Parkinson’s Disease Rating Scale (UPDRS; part III). Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions. Results: The mean standardized BADS scores showed no significant improvement in both the groups. In the de novo group, percent improvement in the standardized BADS scores showed a significant positive correlation with the LED, but not with percent improvement in UPDRS part III. In the chronic medication group, percent improvement in the standardized BADS scores was negatively correlated with change in the LED, but not with percent improvement in UPDRS part III. Multiple regression analysis using improvement in the standardized BADS score as a dependent variable and patient’s background factors (ie, age, education, disease duration, and motor and executive assessments at baseline) as independent variable showed that improvement in the executive assessment is significantly correlated with the LED only in the de novo group. Conclusion: Effects of dopaminergic drug adjustment on executive function differ according to the patient’s clinical stage and depend on LED in de novo stage. Keywords: motor disorders, dopaminergic drug, levodopa equivalent dose, correlation between executive improvement and levodopa equivalent dose, inverted U-shaped theory


1 November 2018 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
ASAzusa Shiromaru-Sugimoto
Azusa Shiromaru-Sugimoto
HMHidetomo Murakami
Hidetomo Murakami
AFAkinori Futamura
Akinori Futamura
MHMotoyasu Honma
Motoyasu Honma
TKTakeshi Kuroda
Takeshi Kuroda
Kenjiro OnoKenjiro Ono
Kenjiro Ono
Background: The relationship between dementia and time perception impairment is unknown. Aim: This study aims to explore subjective perception of the passage of time in patients with Alzheimer’s disease (AD). Methods: We conducted semi-structured interviews with 11 AD patients. Grounded theory, a qualitative research methodology, was used for data analysis. Results: Based on interview transcripts, five categories were designated: {Live according to a private clock}, {The past comes up}, {Move back and forth between the present and the past}, {Cannot imagine the future}, and {Bid farewell to this world as early as tomorrow}. Discussion: Our results suggest that AD patients alternate past and present without complete awareness and cannot imagine a future other than one ending in death.

22 April 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
HMHidetomo Murakami
Hidetomo Murakami
TSTomotaka Shiraishi
Tomotaka Shiraishi
TUTadashi Umehara
Tadashi Umehara
SOShusaku Omoto
Shusaku Omoto
MTMaki Takahashi
Maki Takahashi
YIYasuyuki Iguchi
Yasuyuki Iguchi

19 April 2020 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
HMHidetomo Murakami
Hidetomo Murakami
TSTomotaka Shiraishi
Tomotaka Shiraishi
TUTadashi Umehara
Tadashi Umehara
SOShusaku Omoto
Shusaku Omoto
MTMaki Takahashi
Maki Takahashi
YIYasuyuki Iguchi
Yasuyuki Iguchi